LP(L) – Patentriches

[vc_row css=”.vc_custom_1487913838101{margin-top: -40px !important;}”][vc_column][rev_slider_vc alias=”landing-banner-slider” el_class=”patentriches-slider-section”][/vc_column][/vc_row][vc_row expanded=”2″ background_style=”parallax” background_image=”14503″][vc_column][vc_row_inner el_class=”section-top-padding” css=”.vc_custom_1487959405698{background-color: rgba(255,255,255,0.9) !important;*background-color: rgb(255,255,255) !important;}”][vc_column_inner offset=”vc_col-lg-offset-1 vc_col-lg-10″][vc_column_text]

This technology is a first-of-its-kind and has the potential to change an industry worth billions upon billions of dollars.


When it comes to biotechnology stocks, timing is everything and this stock is about to transition from the lab phase to real world national expansion and exponential growth.

[/vc_column_text][/vc_column_inner][/vc_row_inner][vc_row_inner css=”.vc_custom_1487959682925{background-color: rgba(255,255,255,0.9) !important;*background-color: rgb(255,255,255) !important;}” el_class=”content-padding-grid”][vc_column_inner width=”1/3″][vc_single_image image=”14534″ img_size=”large” alignment=”center” style=”vc_box_outline”][/vc_column_inner][vc_column_inner width=”2/3″][vc_column_text]I have personally sunk my teeth into over 210 companies that own patents and are about to roll out products since October 2016, and nothing even comes close to the combination of well-researched science, aggressive management pressing forward to profitability, a founder that has serious skin in the game, Dr. Sabine Mai, and a series of patents that are secured for 15 years, giving the company a tremendous advantage over any potential competitor.[/vc_column_text][/vc_column_inner][/vc_row_inner][vc_row_inner css=”.vc_custom_1487916983878{background-color: #00429f !important;}” el_class=”section-padding3″][vc_column_inner][section_header use_decoration=”0″ main_heading=”3D Signatures (TSX-V: DXD & OTC: DTSGF) is the only technology company that has a 643% potential.” font_size=”small” color=”#ffffff”][/vc_column_inner][/vc_row_inner][vc_row_inner css=”.vc_custom_1487917608906{background-color: rgba(255,255,255,0.9) !important;*background-color: rgb(255,255,255) !important;}” el_class=”section-padding2″][vc_column_inner][vc_column_text el_class=”patentriches-dark-content-text”]When you invest early in cutting-edge futuristic stocks, you better have one predominant thought in mind: Is this company a potential takeover target.

The huge pay-offs are in the exit and with such a tiny company, large pharmaceutical giants are already lining up to sign Non-Disclosure-Agreements and get involved with the new class of biomarkers.[/vc_column_text][/vc_column_inner][/vc_row_inner][vc_row_inner css=”.vc_custom_1487917363875{background-color: #00429f !important;}” el_class=”section-padding3″][vc_column_inner][section_header use_decoration=”0″ main_heading=”That's why the founder of this company was named one of Canada's most powerful women!” font_size=”small” color=”#ffffff”][section_header use_decoration=”0″ main_heading=”She has been able to execute on the highest level.” font_size=”small” color=”#ffffff”][/vc_column_inner][/vc_row_inner][vc_row_inner css=”.vc_custom_1487916717943{background-color: rgba(255,255,255,0.9) !important;*background-color: rgb(255,255,255) !important;}” el_class=”section-padding2″][vc_column_inner][vc_column_text el_class=”patentriches-dark-content-text”]The Company she founded has over 20 years' worth of research, more than $25 million spent on R&D, and patents in both North America and Europe for its breakthrough discovery.

The reason that this is such a unique window of opportunity is because these scientists have been so hard at work developing the future of diagnosing and custom-fitting a treatment to cancer and 14 types of diseases, according to the patient's specific gene build-up that they have been kept under the radar – until now![/vc_column_text][vc_single_image image=”14557″ img_size=”full” alignment=”center”][vc_column_text]The problem that this company tackles is the most fundamental and basic of all: Are you being treated correctly by your doctor?

Doctors have no clue about what is your specific gene code, and misdiagnosis and worst, mistreatment is one the mega-challenges the medical industry is struggling with.
[/vc_column_text][vc_single_image image=”14562″ img_size=”full” alignment=”center”][vc_column_text]3D Signature' (TSX-V: DXD & OTC: TDSGF) software optimizes treatment – it is the apex and future of precision medicine, where every patient is checked easily and quickly using their proprietary software to find out exactly what is happening with your body and thus allows the most accurate, detailed and specific information about anyone to be placed in front of the doctor, so he can make the most informed decision – tailored to the patient.

It potentially means once we select a treatment, we can know right away if it's working, see if there are any adverse side effects, and know if the treatment is doing more harm than good – all in near real-time.[/vc_column_text][vc_single_image image=”14563″ img_size=”full” alignment=”center”][vc_column_text]

That is why this company is being pursued by giant medical firms!

[/vc_column_text][vc_column_text el_class=”patentriches-dark-content-text”]The one thing no one is talking about, which I was able to figure out after speaking privately with a key individual in the company is that choosing to use the company’s chemical biomarker blood test is a no brainer, since the insurance companies cough up the bill in the majority of cases.

This company holds the patents to software that any patient diagnosed will, no doubt, choose to use, as he’ll want to be super-careful with what course of action he pursues.[/vc_column_text][vc_column_text]

No one plays around or cuts corners when it comes to this type of procedure.

[/vc_column_text][vc_column_text el_class=”patentriches-dark-content-text”]In 12 months from now, laboratories in Canada and then the U.S. will begin to capitalize on 3D Signatures (TSX-V: DXD & OTC: TDSGF) Patented Technology Software, and it will be game over to investors, as the price of the stock will be super-expensive.

3D Signatures is 1 year away from marketing their product to cancer patients in need of the best and most advanced tools to treat their disease and we can invest in the future by positioning now while the company trades for a ridiculous market value of less than $30 Million Dollars![/vc_column_text][/vc_column_inner][/vc_row_inner][vc_row_inner css=”.vc_custom_1488259332764{background-color: rgba(255,255,255,0.9) !important;*background-color: rgb(255,255,255) !important;}” el_class=”section-padding2 formbottom”][vc_column_inner offset=”vc_col-lg-offset-2 vc_col-lg-8 vc_col-md-offset-2 vc_col-md-8″][section_header use_decoration=”0″ main_heading=”Get updates on 3D Signatures and more Wealth Building Ideas for the new economy” color=”#00429f”][vc_column_text el_class=”popup2-form-grid”]

    [/vc_column_text][/vc_column_inner][/vc_row_inner][vc_row_inner css=”.vc_custom_1487916717943{background-color: rgba(255,255,255,0.9) !important;*background-color: rgb(255,255,255) !important;}” el_class=”section-padding2″][vc_column_inner][section_header use_decoration=”0″ main_heading=”Disclaimer” text_align=”left”][vc_column_text]This work is based on SEC filings, current events, interviews, corporate press releases and what we've learned as financial journalists. It may contain errors and you shouldn't make any investment decision based solely on what you read here. It's your money and your responsibility. The information herein is not intended to be personal legal or investment advice and may not be appropriate or applicable for all readers. If personal advice is needed, the services of a qualified legal, investment or tax professional should be sought.[/vc_column_text][vc_column_text]Please read our full disclaimer at PortfolioWealthGlobal.com/disclaimer[/vc_column_text][/vc_column_inner][/vc_row_inner][/vc_column][/vc_row]